Navigation Links
Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
Date:7/9/2008

trials in solid tumor indications, including a Phase III clinical trial in combination with gemcitabine in locally advanced and metastatic pancreatic cancer. Lorus has reported that the overall survival data in this Phase III study did not reach statistical significance, although exploratory analysis yielded promising results in specific patient populations including in patients with ECOG performance status of 0 or 1.

In April 2008, Lorus' subsidiary GeneSense Technologies entered into an exclusive multinational license agreement for Virulizin(R) with Zor Pharmaceuticals LLC to further develop and commercialize Virulizin(R) for advanced pancreatic cancer and other therapy areas in North and South America, Europe, and Israel.

Virulizin(R) study leads to new drug candidate IL-17E

The article entitled "Virulizin(R) induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors" was published online in the journal Cancer Immunology Immunotherapy and is available through PubMed (http://www.ncbi.nlm.nih.gov/PubMed/).

The study showed that Virulizin(R) treatment stimulates the immune system to produce the cytokine IL-17E, which in turn triggers an anticancer effect through activation and tumor recruitment of eosinophils. This novel aspect of the anticancer mechanism of action for Virulizin(R) adds to previous studies showing that Virulizin(R) activates other cells of the immune system, including macrophages and Natural Killer (NK) cells.

A key finding of this report was that IL-17E itself had significant anticancer activity when used in mouse models of human cancers. Preliminary studies have revealed that IL-17E has potent activity against several human tumor types, including colon cancer, melanoma, and pancreatic cancer, with low toxicity. Lorus has patent applications pending in major markets, including Canada, Europe and the United St
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... septembre 2014 Mapi, société créée à ... a été depuis 40 ans l,un des ... traditionnelles par des évaluations recentrées sur le ... impacts économiques des traitements. Logo ... A cours d,une récente conférence téléphonique avec ...
(Date:9/18/2014)... 18, 2014 OMICS Group International ... to participate in the ‘Open Access Week’ by ... OMICS Group Pharma Journals from 20-26th ... the fastest emerging Sciences, accelerating with a tremendous ... across the globe. The industry is gearing with ...
(Date:9/18/2014)... is a group of rare diseases that afflict ... Its onset hits at the fetal stage and ... the gene encoding fibroblast growth factor receptor 3 ... skeletal dysplasia, thanatophoric dysplasia (TD), a skeletal dysplasia ... is often lethal, and achondroplasia (ACH), which causes ...
(Date:9/18/2014)... Artificial sweeteners, promoted as aids to weight loss and ... intolerance and metabolic disease; and they do it in ... of the gut microbiota the substantial population of ... of experiments in mice and humans, were published today ... Eran Elinav of the Weizmann Institute,s Immunology Department, who ...
Breaking Biology Technology:1974 - 2014 - Mapi fête ses 40 ans 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3
... Israel and NEW YORK, October 2 ... on,Company,s Diagnostic and Therapeutic Development Programs, as Well ... (Nasdaq: ROSG ), a global leader in,microRNA-based ... R&D Day on microRNAs and their significant potential ...
... /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS), a ... of technologies targeting the chronic inflammation,underlying cardiovascular and ... close of the North American financial markets,on Tuesday, ... web cast will also,be conducted on Tuesday, October ...
... 2 Othera Pharmaceuticals, Inc., a,specialty pharmaceuticals ... oncology, and inflammatory disease, has,announced the appointment ... Chief,Scientific Officer effective immediately. In this position, ... execution of Othera,s research,and clinical development programs. ...
Cached Biology Technology:Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007 2Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007 3Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007 4Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 2Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 3Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 4Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer 2Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer 3
(Date:9/18/2014)... and their colleagues have built the first smartphone ... performance and behavioral trends. In other words, your ... if you don,t -- and how that affects ... happiness, stress, depression and loneliness to their academic ... population for example, to monitor mental health, ...
(Date:9/18/2014)... algal forests in the eastern Mediterranean Sea pose a ... distribution continues to expand as the climate warms, a ... of researchers led by Dr Adriana Vergs of UNSW ... for Advanced Studies in Spain, is published in the ... surveyed more than 1000 kilometres of coastline in Turkey ...
(Date:9/18/2014)... ultimate form of camouflage: you don,t just blend in, ... not as uncommon as you might think. Kathryn Feller, ... that the larval life stages of many marine species ... anatomy that most creatures cannot make transparent. Feller explains ... each individual eye unit with an opaque pigment to ...
Breaking Biology News(10 mins):New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Tropical fish a threat to Mediterranean Sea ecosystems 2Transparent larvae hide opaque eyes behind reflections 2
... can counteract the effects of tumor-promoting molecules in skin ... University of Pennsylvania School of Medicine. Using animal models, ... in epithelial cells, preventing uncontrolled cell growth caused by ... published online in the Journal of Biological Chemistry, suggests ...
... suffering chronic obstructive pulmonary disease (COPD) attempt to ... contradicts the conventional wisdom on the capabilities of ... attempted regional elastic fiber repair in severe emphysema," ... Patterson and Richard Pierce of Washington University, St. ...
... neurons may have been a key factor in why ... primate relatives. In a study comparing the genomes of ... U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley ... high degree of genetic differences in DNA sequences that ...
Cached Biology News:Signal protein shows promise for blocking tumor promoters in skin cells 2Lungs try to repair damaged elastic fibers 2Neuron cell stickiness may hold key to evolution of the human brain 2Neuron cell stickiness may hold key to evolution of the human brain 3Neuron cell stickiness may hold key to evolution of the human brain 4
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside ... Br Cl N O 6 ... (HPLC) ,Solution: Clear (2% in DMF) ... pUC and M13 ,Elemental Analysis: Agrees ...
Antibodies were affinity purified using epitopes specific to RFC1 immobilized on solid support....
Biology Products: